The SVP HR of Boston Scientific (BSX) is Selling Shares

Yesterday, the SVP HR of Boston Scientific (BSX), Wendy Carruthers, sold shares of BSX for $399.3K.

Following Wendy Carruthers’ last BSX Sell transaction on June 03, 2013, the stock climbed by 31.4%. In addition to Wendy Carruthers, one other BSX executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

The company has a one-year high of $46.62 and a one-year low of $24.10. BSX’s market cap is $58.34 billion and the company has a P/E ratio of 14.10.

Based on 15 analyst ratings, the analyst consensus is Strong Buy with an average price target of $45.93, reflecting a -11.4% downside.

The insider sentiment on Boston Scientific has been negative according to 91 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Read More on BSX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts